This study observed the effect of medical cannabis in benign essential blepharospasm (BEB), in addition to standard botulinum toxin treatment. The study comprised of a retrospective chart review on eligible patients and included information on patient demographics, responses, cannabis history and severity indices. There were a total of ten patients certified for medical cannabis use and five of these met the inclusion criteria for this study. Of the five patients, four discontinued use, three out of these four (75%) reported symptomatic improvement. Of the five patients in the study, only one had to stop treatment due to concerns of an adverse event. The study concluded that the medical use of cannabis as an adjunctive therapy for BEB remains unknown and that further research would be beneficial to explore its effect. This study is limited by sample size and retrospective design, with a short follow-up time. The findings offer a backdrop to exploring the effects of cannabis in this setting, which needs further investigation before its use is likely to be advocated.